New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSemax vs P21

Semax vs P21

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Semax
Cognitive EnhancementAnti-Aging & Longevity
P21
Summary
Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Half-Life
Minutes (but effects persist for hours via BDNF induction)
Not well characterized; likely short, but neurogenic effects persist long after administration
Admin Route
Intranasal, SubQ
SubQ, Intranasal
Research
Typical Dose
0.25–1 mg (250–1000 mcg)
100–500 mcg
Frequency
1–2 times daily
Once daily
Key Benefits
  • Enhances memory and learning
  • Improves focus and concentration
  • Increases mental energy and motivation
  • Provides neuroprotection via BDNF and NGF upregulation
  • Reduces cognitive decline
  • May alleviate ADHD symptoms
  • Supports recovery from brain injury and stroke
  • Fast-acting — effects within 30–60 minutes
  • Approved in Russia for cognitive disorders and stroke recovery
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
Side Effects
  • Headache (rare, often from higher doses)
  • Anxiety or overstimulation at high doses
  • Sleep disruption if dosed too late
  • Irritability (uncommon)
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
Stacks With